Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: Report of three cases

Mishra, Abha; Ghosh, Amerta; Dutta, Koel; Tyagi, Kanika; Misra, Anoop

doi:10.1016/j.dsx.2021.05.024

Cited by 31 publications

(27 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thalamic dysfunction can disrupt important connections for the coordination of movement and develop aberrant pathway which can evoke abnormal involuntary movements. In ChAdOx1 adeno-virus vector vaccine, sudden increasing serum glucose level following vaccination has been reported in some cases [ 5 ]. In addition, other systemic illness may induce embolism, which can cause thalamic dysfunction or hypoperfusion.…”

mentioning

confidence: 99%

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine

2021

View full text Add to dashboard Cite

mentioning

confidence: 99%

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine

2021

View full text Add to dashboard Cite

“…There has been a documented case of new-onset type 2 diabetes mellitus presenting as the hyperosmolar hyperglycemic state (HHS) [ 69 ], 3 cases of fasting and postprandial hyperglycemia in patients with well-controlled type 2 diabetes mellitus [ 70 ], and transient hypoglycemia in patients with type 1 diabetes mellitus on basal-bolus insulin regimens after COVID-19 vaccination [ 71 ], described in Table 1 .…”

Section: Methodsmentioning

confidence: 99%

COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation

Mirza

Sheikh

Barbera

et al. 2022

Infectious Disease Reports

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) infection primarily involves the respiratory system but has many noteworthy extra pulmonary manifestations as well. We write this review to highlight the basis of some pathophysiological mechanisms of COVID-19 infection-induced endocrine dysfunction. Different scientific databases and institutional websites were searched to collect and consolidate the most up-to-date data relating to COVID-19 infection and endocrine systems. Hypopituitarism, central diabetes insipidus, SIADH, thyroid abnormalities, hyperglycemia, adrenal insufficiency, orchitis and alteration in sperm morphology have been reported in case reports of patients with COVID-19 infection. Data focusing on COVID-19 vaccination was also searched to summarize the effect, if any, on the endocrine system. Endocrinopathies noted post COVID-19 vaccination, including cases of adrenal hemorrhage, new onset Type II Diabetes Mellitus and subacute thyroiditis, are also discussed in this review. This review calls attention to the misinformation relating to COVID-19 vaccination with supposed endocrine effects such as infertility and problems with pregnancy. Rebutting these misconceptions can help increase compliance and maximize COVID-19 vaccination to the public.

show abstract

“…Several instances of COVID-19 vaccination-induced hyperglycemia (ViHG) and related complications were reported [ 10 , 11 , 12 , 13 ]. Three diabetic individuals (one female and two males) presented with postvaccination hyperglycemia 1–6 days after receiving their first dose of the Covishield (AstraZeneca) vaccine [ 13 ]. The hyperglycemia persisted for about 30 days in the female and required a higher metformin dosage to achieve glycemic control [ 13 ].…”

Section: Vaccine-induced Hyperglycemia (Vihg)—case Reportsmentioning

confidence: 99%

“…Three diabetic individuals (one female and two males) presented with postvaccination hyperglycemia 1–6 days after receiving their first dose of the Covishield (AstraZeneca) vaccine [ 13 ]. The hyperglycemia persisted for about 30 days in the female and required a higher metformin dosage to achieve glycemic control [ 13 ]. The males achieved glycemic control in 3–15 days without additional antihyperglycemic intervention [ 13 ].…”

Section: Vaccine-induced Hyperglycemia (Vihg)—case Reportsmentioning

confidence: 99%

COVID-19 Vaccines and Hyperglycemia—Is There a Need for Postvaccination Surveillance?

et al. 2022

View full text Add to dashboard Cite

The COVID-19 vaccines currently in use have undoubtedly played the most significant role in combating the SARS-CoV-2 virus and reducing disease severity and the risk of death among those affected, especially among those with pre-existing conditions, such as diabetes. The management of blood glucose levels has become critical in the context of the COVID-19 pandemic, where data show two- to threefold higher intensive care hospital admissions and more than twice the mortality rate among diabetic COVID-19 patients when compared with their nondiabetic counterparts. Furthermore, new-onset diabetes and severe hyperglycemia-related complications, such as hyperosmolar hyperglycemic syndrome (HHS) and diabetic ketoacidosis (DKA), were reported in COVID-19 patients. However, irrespective of the kind of vaccine and dosage number, possible vaccination-induced hyperglycemia and associated complications were reported among vaccinated individuals. The current article summarizes the available case reports on COVID-19 vaccination-induced hyperglycemia, the possible molecular mechanism responsible for this phenomenon, and the outstanding questions that need to be addressed and discusses the need to identify at-risk individuals and promote postvaccination monitoring/surveillance among at-risk individuals.

show abstract

Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: Report of three cases

Cited by 31 publications

References 3 publications

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine

COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation

COVID-19 Vaccines and Hyperglycemia—Is There a Need for Postvaccination Surveillance?

Contact Info

Product

Resources

About